KIT and systemic mastocytosis: The current hypothesis is that these additional mutations (most commonly in: TET2, SRSF2, ASXL1, CBL, RUNX1, and RAS) act together with KIT D816V in advanced SM to trigger proliferation and survival of neoplastic MCs.